More than two-thirds of new drugs approved by FDA in 2024 were based on a single study
• A new analysis reveals that more than two-thirds of new drugs approved by the FDA in 2024 were sanctioned based on the findings of a single study. • The report indicates a steady decline in the number of studies required for drug approval since 2016, raising concerns about the rigor of the process. • Researchers argue that this trend necessitates stronger post-market surveillance and more comprehensive trial reporting to maintain the integrity of drug approvals.
cidrap.umn.edu





